Jing Hong Wang, MD, PhD
- Professor, Department of Medicine, Division of Hematology/Oncology
- UPMC Hillman Cancer Center
Education & Training
- Postdoctoral Fellow, Children’s Hospital Boston and Harvard Medical School, Boston, MA, 2009
- PhD in Immunology, University of Chicago, 2004
- MS, Ohio State University, Columbus, OH, 1998
- MD, Beijing Medical University (now known Peking University Health Science Center), 1996
Research Interest Summary
Research Interests
We employ genetic and immunological approaches to better understand the interplay of cancer and immune system. Given the evolutionary characteristics of cancer cells manifested as a high level of complexity, flexibility, and heterogeneity, we envision that only the immune system may be able to fight cancers with equal adaptability and specificity. Our B-cell lymphoma studies focus on elucidating how B-cell intrinsic process that is required for effective humoral immunity may contribute to B-cell lymphomagenesis, why B-cells are so prone to develop lymphomas and how malignant B-cells evade immune surveillance. Our HNSCC studies focus on elucidating the mechanisms of heterogeneous anti-tumor immune responses, in particular, why certain individuals can eradicate cancers while others succumb to cancer progression, and why different individuals respond differentially to anti-cancer therapy. The goals of my research program include: (1) define the cellular and molecular mechanisms of immune evasion during cancer development; (2) develop more effective cancer immunotherapy, with a focus on HNSCCs and B cell lymphomas; (3) elucidate the basic mechanisms of antibody gene diversification and B cell lymphomagenesis.
Publications
1) Cetuximab responses in patients with HNSCC correlate to clonal expansion feature of peripheral and tumor-infiltrating T cells with top T-cell receptor clonotypes H Ge, RL Ferris, JH Wang Clinical Cancer Research 29 (3), 647-658
2) Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers SMY Chen, V Popolizio, RA Woolaver, H Ge, AL Krinsky, J John, E Danis, ... Journal of Experimental & Clinical Cancer Research 41 (1), 123
3) Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts RA Woolaver, X Wang, AL Krinsky, BC Waschke, SMY Chen, V Popolizio, ... Journal for Immunotherapy of Cancer 9 (1), e001615
4) Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas X Wang, BC Waschke, RA Woolaver, Z Chen, G Zhang, AD Piscopio, ... Cancer immunology research 7 (8), 1318-1331
5) Sequence-intrinsic mechanisms that target AID mutational outcomes on antibody genes LS Yeap, JK Hwang, Z Du, RM Meyers, FL Meng, A Jakubauskaitė, M Liu, ... Cell 163 (5), 1124-1137